David N. Cook

3.3k total citations · 1 hit paper
25 papers, 2.2k citations indexed

About

David N. Cook is a scholar working on Molecular Biology, Genetics and Infectious Diseases. According to data from OpenAlex, David N. Cook has authored 25 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 6 papers in Genetics and 5 papers in Infectious Diseases. Recurrent topics in David N. Cook's work include Gut microbiota and health (7 papers), Clostridium difficile and Clostridium perfringens research (5 papers) and Photosynthetic Processes and Mechanisms (4 papers). David N. Cook is often cited by papers focused on Gut microbiota and health (7 papers), Clostridium difficile and Clostridium perfringens research (5 papers) and Photosynthetic Processes and Mechanisms (4 papers). David N. Cook collaborates with scholars based in United States, United Kingdom and Japan. David N. Cook's co-authors include John E. Hearst, Hiroshi Nikaido, Ning G. Pon, Marie Alberti, Dzwokai Ma, D Ma, Thomas W. Dubensky, Martin Giedlin, Dirk G. Brockstedt and Keith S. Bahjat and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

David N. Cook

25 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genes acrA and acrB encode a stress‐induced efflux system of Escherichia coli

1995 511 citations Dzwokai Ma, David N. Cook et al. Molecular Microbiology profile →

Peers

Countries citing papers authored by David N. Cook

Since Specialization

Citations

This map shows the geographic impact of David N. Cook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David N. Cook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David N. Cook more than expected).

Fields of papers citing papers by David N. Cook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David N. Cook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David N. Cook. The network helps show where David N. Cook may publish in the future.

Co-authorship network of co-authors of David N. Cook

This figure shows the co-authorship network connecting the top 25 collaborators of David N. Cook. A scholar is included among the top collaborators of David N. Cook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David N. Cook. David N. Cook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML 2025 ·Journal of Hematology & Oncology ·Brian Ball, Wenbin Xiao, Gautam Borthakur, Le Xuan Truong Nguyen, (unknown), Avanthika Venkatachalam, Guido Marcucci, Anthony S. Stein, Dung Thai, David N. Cook, Kyle Chan, (unknown), Ross L. Levine, Omar Abdel‐Wahab, Yinon Ben‐Neriah, Eytan M. Stein	1
2	Dosing a synbiotic of human milk oligosaccharides and B. infantis leads to reversible engraftment in healthy adult microbiomes without antibiotics 2022 ·Cell Host & Microbe ·Julie E. Button, Chloe Autran, (unknown), Casey M. Cosetta, Steven Smriga, (unknown), Jessica V. Pierce, David N. Cook, Martin L. Lee, (unknown), Amin M. Alousi, Andrew Y. Koh, David J. Rechtman, Robert R. Jenq, Gregory J. McKenzie	56
3	Abstract B063: Leveraging gut microbiota networks to impact tumor immunotherapy 2019 ·Cancer Immunology Research ·Lata Jayaraman, Jaclyn Sceneay, Srimathi Srinivasan, (unknown), (unknown), (unknown), George E. Marnellos, Christopher A. Desjardins, Jennifer R. Wortman, Matthew R. Henn, David N. Cook	1
4	Tu2019 - Engraftment of Ser-287, an Investigational Microbiome Therapeutic, is Related to Clinical Remission in a Placebo-Controlled, Double-Blind Randomized Trial (Seres-101) in Patients with Active Mild to Moderate Ulcerative Colitis (UC) 2018 ·Gastroenterology ·Sheri L. Simmons, (unknown), Edward R. O’Brien, Meghan Chafee, (unknown), Patricia Bernardo, David N. Cook, Michele Trucksis, Matthew R. Henn	3
5	621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner 2018 ·Open Forum Infectious Diseases ·Matthew R. Henn, Christopher B. Ford, Edward R. O’Brien, Jennifer R. Wortman, (unknown), Christopher A. Desjardins, Amelia D. Tomlinson, (unknown), Mark H. Wilcox, Anthony M. Buckley, Patricia Bernardo, Barbara McGovern, John Auniņš, David N. Cook, Michele Trucksis	1
6	1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes 2018 ·Open Forum Infectious Diseases ·Christopher B. Ford, Matthew R. Henn, Jessica A. Bryant, (unknown), Jennifer R. Wortman, Amelia D. Tomlinson, (unknown), Patricia Bernardo, Barbara McGovern, John Auniņš, David N. Cook, Michele Trucksis	1
7	Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI) 2017 ·Open Forum Infectious Diseases ·Matthew R. Henn, Christopher B. Ford, Edward R. O’Brien, Jennifer R. Wortman, Sheri L. Simmons, (unknown), (unknown), Patricia Bernardo, John Auniņš, David N. Cook, Michele Trucksis	3
8	A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents RecurrentClostridium difficileInfection 2016 ·The Journal of Infectious Diseases ·Sahil Khanna, Darrell S. Pardi, Colleen Kelly, Colleen S. Kraft, Tanvi Dhere, Matthew R. Henn, Mary-Jane Lombardo, Marin Vulić, Toshiro K. Ohsumi, Jonathan Winkler, Christina Pindar, Barbara McGovern, Roger J. Pomerantz, John Auniņš, David N. Cook, Elizabeth Hohmann	230
9	Selective Targeting of Antitumor Immune Responses with Engineered Live-Attenuated Listeria monocytogenes 2006 ·Cancer Research ·Kiyoshi Yoshimura, Ajay Jain, Heather E. Allen, (unknown), Christina Y. Chia, Sowmya Ravi, Dirk G. Brockstedt, Martin Giedlin, Keith S. Bahjat, Meredith L. Leong, Jill E. Slansky, David N. Cook, Thomas W. Dubensky, Drew M. Pardoll, Richard D. Schulick	48
10	Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity 2005 ·Nature Medicine ·Dirk G. Brockstedt, Keith S. Bahjat, Martin Giedlin, (unknown), (unknown), William Luckett, Yi Gao, Pamela Schnupf, (unknown), (unknown), (unknown), Adam Sampson-Johannes, Anat A. Herskovits, Adonis Stassinopoulos, H. G. Archie Bouwer, J Hearst, Daniel A. Portnoy, David N. Cook, Thomas W. Dubensky	114
11	Listeria-based cancer vaccines that segregate immunogenicity from toxicity 2004 ·Proceedings of the National Academy of Sciences ·Dirk G. Brockstedt, Martin Giedlin, Meredith L. Leong, Keith S. Bahjat, Yi Qin Gao, William Luckett, Weiqun Liu, David N. Cook, Daniel A. Portnoy, Thomas W. Dubensky	239
12	Vesicular stomatitis virus 2003 ·Cancer Cell ·Martin Giedlin, David N. Cook, Thomas W. Dubensky	33
13	Genes acrA and acrB encode a stress‐induced efflux system of Escherichia coli breakdown → 1995 ·Molecular Microbiology ·Dzwokai Ma, David N. Cook, Marie Alberti, Ning G. Pon, Hiroshi Nikaido, John E. Hearst	511
14	Efflux pumps and drug resistance in Gram-negative bacteria 1994 ·Trends in Microbiology ·Dzwokai Ma, David N. Cook, John E. Hearst, Hiroshi Nikaido	247
15	Molecular cloning and characterization of acrA and acrE genes of Escherichia coli 1993 ·Journal of Bacteriology ·D Ma, David N. Cook, Marie Alberti, Ning G. Pon, Hiroshi Nikaido, John E. Hearst	389
16	Regulation of carotenoid and bacteriochlorophyll biosynthesis genes and identification of an evolutionarily conserved gene required for bacteriochlorophyll accumulation 1993 ·Journal of General Microbiology ·G. A. Armstrong, David N. Cook, D Ma, Marie Alberti, Donald H. Burke, John E. Hearst	20
17	Analysis of the promoter and regulatory sequences of an oxygen-regulated bch operon in Rhodobacter capsulatus by site-directed mutagenesis 1993 ·Journal of Bacteriology ·D Ma, David N. Cook, David O’Brien, John E. Hearst	43
18	Torsional Rigidity of Positively and Negatively Supercoiled DNA 1992 ·Science ·Paul R. Selvin, David N. Cook, Ning G. Pon, William R. Bauer, Melvin P. Klein, John E. Hearst	54
19	Induction of anaerobic gene expression in Rhodobacter capsulatus is not accompanied by a local change in chromosomal supercoiling as measured by a novel assay 1989 ·Journal of Bacteriology ·David N. Cook, G. A. Armstrong, John E. Hearst	28
20	Oxygen-regulated mRNAs for light-harvesting and reaction center complexes and for bacteriochlorophyll and carotenoid biosynthesis in Rhodobacter capsulatus during the shift from anaerobic to aerobic growth 1986 ·Journal of Bacteriology ·Yongsheng Zhu, David N. Cook, Francesca Leach, G. A. Armstrong, Marie Alberti, John E. Hearst	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact